N/A N=10 Continuous Glucose Monitoring in Adolescents With Poorly Controlled Type 1 Diabetes
Type 1 Diabetes
Primary: Number of High Glucose Correction Doses Administered. — 0; 2; 2; 5 sensor/plasma glucose-based insulin dose
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=54 Multiple Doses of AT-1501-A201 in Adults With ALS
Amyotrophic Lateral Sclerosis
Primary: Safety and Tolerability — 8; 8; 10; 16 participants
N/A N=48 Virtual Reality to Improve Social Perspective Taking
Conduct Disorder · Child · Adolescent
Primary: Change From Pre-intervention on the Virtual Reality Perspective Taking Scale — 16.3; -10.4 Score on a scale
Phase 3 N=330 A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients
Nasopharyngeal Carcinoma
Primary: Overall Survival (OS) of Subjects With Advanced Nasopharyngeal Carcinoma. — 25; 24.9 Months — p=0.1942
Phase 3 N=314 Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men
Hypogonadism, Male
Primary: Percentage of Male Hypogonadal Subjects With Average NaF/EDTA Plasma Total Testosterone (T Cavg) Within the Normal Range Using Oral SOV2012-F1. — 166 Participants
N/A N=49 Alcohol Monitor Validation
Human Immunodeficiency Virus (HIV)
Primary: Transdermal Alcohol Concentration (TAC) — 38.3; 95.8 ug/L
N/A N=63 Study of a PST-Trained Voice-Enabled Artificial Intelligence Counselor (SPEAC) for Adults With Emotional Distress (Phase 1)
Depression · Anxiety
Primary: Change in Activation of Left Amygdala From Baseline Functional Magnetic Resonance Scan at 16 Weeks — -0.07; -0.13 beta weights
Phase 1 N=8 Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)
Metastatic Castration Resistant Prostate Cancer
Primary: Evaluate the PK of Rucaparib in Combination With Other Anticancer Agents for mCRPC. — 1345; 233; 1558; 311 ng/ml
N/A N=11 Assessment of Methadone and Buprenorphine in Interstitial Fluid
Opioid Use Disorder
Primary: Methadone Concentration in Plasma and Interstitial Fluid (ISF) Before and After Taking a Dose — 565; 640; 760; 2000 ng/ml
N/A N=162 Calypso Knee System Clinical Study
Osteoarthritis, Knee
Primary: Composite Clinical Success (CCS) — 83.5; 57.2 percentage of subjects
Phase 2 N=36 Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL
Lymphoid Leukemia · Small Lymphocytic Lymphoma · Lymphoma, Non-Hodgkin
Primary: Time to Progression — 4.76 years
Phase 2 N=95 Thiamine as a Renal Protective Agent in Septic Shock
Sepsis · Kidney Injury · Thiamine Deficiency
Primary: Kidney Injury Biomarker — 2.24; 2.79 mg/dL — p=0.07
Phase 4 N=28 Chronotherapy in Inflammatory Bowel Disease
Inflammatory Bowel Diseases
Primary: Thioguanine Levels in Blood (Morning Versus Evening Dosing) — 175.04; 225.65 pmol/8 x 10^8 RBC
N/A N=74 Clinical Assessment of a Daily Wear Monthly Replacement Silicone Hydrogel Toric Contact Lens
Refractive Errors · Astigmatism
Primary: Distance Visual Acuity (VA) With Study Lenses — -0.06; -0.07; -0.08; -0.06 logMAR
N/A N=19 Study Evaluating Treatment of Upper Limb Spasticity Using the Cryo-Touch III Device
Upper Limb Spasticity
Primary: Decrease in Pain and Symptoms Caused by Hypertonia in the Upper Arm as Measured by an Improvement of 1 Point or Greater on the Modified Ashworth Scale (MAS) at Day 7…